A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

NCT01092104 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: TBR-652
DRUG: TBR-652 Matching Placebo
DRUG: TBR-652 50 mg
DRUG: TBR-652 75 mg
DRUG: TBR-652 100 mg
DRUG: TBR-652 150 mg

Sponsor

Tobira Therapeutics, Inc.